Vaxcyte, Inc. (PCVX)
Every FINRA and SEC series the site collects for Vaxcyte, Inc.: short interest with days to cover, daily short sale volume, fails to deliver and Form 4 insider trades. Listed on Nasdaq, classified by the SEC as biological products, (no diagnostic substances).
14.8M
Short interest
settlement 2026-08-14
15.8
Days to cover
+2.3% vs prior
93.3%
Short share of volume
2026-09-11
620
Fails to deliver
settlement 2026-08-06
-$1.8M
Insider flow, 90 days
0 buys, 9 sells
As of 2026-09-11.
Short interest
FINRA, twice a month; the last 12 months shown, all 48 settlements in the JSONAs of 14 August 2026, short interest in PCVX is 14,796,265 shares, up 564,346 shares over the last month. Over the last 48 readings it ranged from 8,574,767 shares (31 October 2025) to 17,468,070 shares (30 June 2026). At the reported average volume of 933K shares a day that is 15.8 days to cover, a crowded short.
Embed this chartfree, with the attribution line it carries
<iframe src="https://xoomar.com/embed/stocks/pcvx" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-08-14 | 14,796,265 | +2.3% | 933,368 | 15.85 |
| 2026-07-31 | 14,464,951 | +1.6% | 976,182 | 14.82 |
| 2026-07-15 | 14,231,919 | -18.5% | 1,150,360 | 12.37 |
| 2026-06-30 | 17,468,070 | +19.4% | 2,527,630 | 6.91 |
| 2026-06-15 | 14,629,103 | +1.1% | 1,363,059 | 10.73 |
| 2026-05-29 | 14,473,801 | +5.0% | 1,635,319 | 8.85 |
| 2026-05-15 | 13,789,778 | -2.5% | 1,778,976 | 7.75 |
| 2026-04-30 | 14,143,473 | -1.5% | 1,080,727 | 13.09 |
| 2026-04-15 | 14,356,548 | +4.9% | 1,221,940 | 11.75 |
| 2026-03-31 | 13,685,643 | +4.7% | 1,400,092 | 9.77 |
| 2026-03-13 | 13,067,798 | -1.4% | 1,200,307 | 10.89 |
| 2026-02-27 | 13,257,134 | -3.6% | 1,236,961 | 10.72 |
| 2026-02-13 | 13,755,621 | +15.1% | 1,751,323 | 7.85 |
| 2026-01-30 | 11,953,116 | -1.2% | 1,591,696 | 7.51 |
| 2026-01-15 | 12,095,806 | +1.6% | 968,645 | 12.49 |
| 2025-12-31 | 11,905,942 | +10.0% | 1,214,209 | 9.81 |
| 2025-12-15 | 10,827,314 | +5.1% | 1,634,980 | 6.62 |
| 2025-11-28 | 10,301,208 | +10.3% | 1,342,585 | 7.67 |
| 2025-11-14 | 9,336,796 | +8.9% | 1,472,299 | 6.34 |
| 2025-10-31 | 8,574,767 | -14.4% | 1,305,648 | 6.57 |
| 2025-10-15 | 10,013,969 | -9.6% | 2,090,752 | 4.79 |
| 2025-09-30 | 11,081,540 | -2.4% | 2,231,666 | 4.97 |
| 2025-09-15 | 11,355,857 | -1.3% | 1,543,818 | 7.36 |
| 2025-08-29 | 11,505,613 | +0.6% | 1,394,842 | 8.25 |
Daily short volume
FINRA Reg SHO, last 60 sessions. JSONAs of 11 September 2026, the short share of PCVX volume is 93.3%, up 15.7 points over the last five sessions. Over the last 52 readings it ranged from 39.9% (24 July 2026) to 93.3% (11 September 2026). The latest reading sits at the top of that range. The latest reading is 21.3 points above the 30-session average of 71.9%, on 1.1M shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-09-11 | 1.0M | 1.1M | 93.3% | 274 |
| 2026-09-10 | 444K | 529K | 83.9% | 2,371 |
| 2026-09-09 | 313K | 451K | 69.5% | 209 |
| 2026-09-08 | 229K | 368K | 62.2% | 129 |
| 2026-09-04 | 201K | 246K | 81.7% | 4,243 |
| 2026-09-03 | 218K | 281K | 77.6% | 80 |
| 2026-09-02 | 217K | 288K | 75.4% | 1,387 |
| 2026-09-01 | 364K | 657K | 55.4% | 7,425 |
| 2026-08-31 | 372K | 628K | 59.1% | 333 |
| 2026-08-28 | 250K | 302K | 82.8% | 1 |
| 2026-08-27 | 166K | 250K | 66.4% | 0 |
| 2026-08-26 | 153K | 353K | 43.4% | 357 |
| 2026-08-25 | 233K | 418K | 55.8% | 0 |
| 2026-08-24 | 170K | 272K | 62.5% | 60 |
| 2026-08-21 | 280K | 362K | 77.5% | 3,371 |
| 2026-08-20 | 210K | 254K | 82.8% | 1,474 |
| 2026-08-19 | 512K | 608K | 84.2% | 7,757 |
| 2026-08-18 | 137K | 186K | 73.9% | 0 |
| 2026-08-17 | 211K | 254K | 83.0% | 978 |
| 2026-08-14 | 127K | 199K | 63.9% | 0 |
| 2026-08-13 | 330K | 392K | 84.4% | 0 |
| 2026-08-12 | 429K | 514K | 83.6% | 4,041 |
| 2026-08-11 | 236K | 310K | 76.1% | 3,250 |
| 2026-08-10 | 258K | 359K | 71.9% | 1,129 |
| 2026-08-07 | 435K | 602K | 72.2% | 4,338 |
| 2026-08-06 | 347K | 484K | 71.7% | 1,539 |
| 2026-08-05 | 153K | 227K | 67.6% | 431 |
| 2026-08-04 | 152K | 262K | 57.9% | 0 |
| 2026-08-03 | 184K | 329K | 56.0% | 0 |
| 2026-07-31 | 211K | 256K | 82.4% | 40 |
Fails to deliver
SEC, by settlement date. JSONAs of 6 August 2026, the fails-to-deliver balance in PCVX is 620 shares, down 2,317 shares over the last settlement date. Over the last 52 readings it ranged from 1 share (10 September 2025) to 44,128 shares (3 October 2025). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-08-06 | 620 | $55.92 | $35K |
| 2026-08-04 | 2,937 | $53.53 | $157K |
| 2026-07-23 | 266 | $56.00 | $15K |
| 2026-07-20 | 187 | $56.20 | $11K |
| 2026-07-16 | 55 | $56.74 | $3K |
| 2026-06-30 | 6,551 | $57.72 | $378K |
| 2026-06-29 | 655 | $56.52 | $37K |
| 2026-06-26 | 179 | $53.68 | $10K |
| 2026-06-24 | 158 | $51.96 | $8K |
| 2026-06-18 | 38 | $50.67 | $2K |
| 2026-06-05 | 3,848 | $48.76 | $188K |
| 2026-04-20 | 2,999 | $62.35 | $187K |
| 2026-04-16 | 12,084 | $60.45 | $730K |
| 2026-04-14 | 113 | $61.75 | $7K |
| 2026-04-09 | 18 | $60.10 | $1K |
| 2026-03-31 | 2 | $54.96 | $110 |
| 2026-03-24 | 2 | $55.94 | $112 |
| 2026-03-23 | 15 | $54.72 | $821 |
| 2026-03-20 | 2 | $53.98 | $108 |
| 2026-03-06 | 11,599 | $58.25 | $676K |
| 2026-02-24 | 3,833 | $60.26 | $231K |
| 2026-02-23 | 100 | $58.51 | $6K |
| 2026-02-09 | 323 | $56.15 | $18K |
| 2026-02-02 | 19,502 | $53.57 | $1.0M |
| 2026-01-29 | 210 | $51.37 | $11K |
| 2026-01-23 | 88 | $53.83 | $5K |
| 2026-01-12 | 71 | $46.05 | $3K |
| 2026-01-05 | 50 | $46.46 | $2K |
| 2025-12-30 | 19 | $46.57 | $885 |
| 2025-12-22 | 60 | $46.42 | $3K |
Insider trades
SEC Form 4, newest first, 50 of 99 shown. JSONInsiders at PCVX reported 9 open-market sells worth $1.8M in the last 90 days and no open-market buys. Sells alone are a weak signal; insiders sell for tax, diversification and estate reasons all the time. Latest filing: GUGGENHIME ANDREW (PRESIDENT AND CFO) on 2026-09-08.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-09-08 | GUGGENHIME ANDREW | PRESIDENT AND CFO | Tax withholding | 7K | $60.36 | $432K | 95K |
| 2026-09-08 | Dhaliwal Harpreet S. | Chief Technical Ops Officer | Tax withholding | 8K | $60.36 | $462K | 68K |
| 2026-09-08 | Cowan Elvia | SVP, Finance & CAO | Tax withholding | 1K | $60.36 | $80K | 28K |
| 2026-09-04 | Jodar Luis | Chief Medical Officer | Grant | 53K | $0.00 | $0 | 53K |
| 2026-09-02 | Wassil Jim | CHIEF OPERATING OFFICER | Tax withholding | 1K | $61.58 | $88K | 154K |
| 2026-09-02 | PICKERING GRANT | CHIEF EXECUTIVE OFFICER | Tax withholding | 3K | $61.58 | $211K | 447K |
| 2026-09-02 | GUGGENHIME ANDREW | PRESIDENT AND CFO | Tax withholding | 1K | $61.58 | $88K | 102K |
| 2026-09-02 | Dhaliwal Harpreet S. | Chief Technical Ops Officer | Tax withholding | 659 | $61.58 | $41K | 76K |
| 2026-09-02 | Cowan Elvia | SVP, Finance & CAO | Tax withholding | 326 | $61.58 | $20K | 29K |
| 2026-09-01 | Wassil Jim | CHIEF OPERATING OFFICER | Sell | 303 | $61.42 | $19K | 155K |
| 2026-09-01 | Wassil Jim | CHIEF OPERATING OFFICER | Sell | 924 | $60.95 | $56K | 155K |
| 2026-09-01 | Wassil Jim | CHIEF OPERATING OFFICER | Sell | 713 | $61.48 | $44K | 156K |
| 2026-09-01 | Wassil Jim | CHIEF OPERATING OFFICER | Sell | 2K | $60.89 | $94K | 157K |
| 2026-09-01 | Wassil Jim | CHIEF OPERATING OFFICER | Option exercise | 2K | $5.35 | $12K | 159K |
| 2026-08-31 | Wassil Jim | CHIEF OPERATING OFFICER | Tax withholding | 1K | $60.74 | $77K | 156K |
| 2026-08-31 | PICKERING GRANT | CHIEF EXECUTIVE OFFICER | Tax withholding | 3K | $60.74 | $174K | 450K |
| 2026-08-31 | GUGGENHIME ANDREW | PRESIDENT AND CFO | Tax withholding | 1K | $60.74 | $77K | 104K |
| 2026-08-31 | Dhaliwal Harpreet S. | Chief Technical Ops Officer | Tax withholding | 361 | $60.74 | $22K | 76K |
| 2026-08-31 | Cowan Elvia | SVP, Finance & CAO | Tax withholding | 243 | $60.74 | $15K | 30K |
| 2026-08-05 | Dhaliwal Harpreet S. | Chief Technical Ops Officer | Sell | 17K | $55.00 | $935K | 77K |
| 2026-08-05 | Dhaliwal Harpreet S. | Chief Technical Ops Officer | Option exercise | 17K | $24.79 | $421K | 94K |
| 2026-08-03 | Wassil Jim | CHIEF OPERATING OFFICER | Sell | 1K | $54.09 | $75K | 158K |
| 2026-08-03 | Wassil Jim | CHIEF OPERATING OFFICER | Sell | 861 | $53.50 | $46K | 159K |
| 2026-08-03 | Wassil Jim | CHIEF OPERATING OFFICER | Option exercise | 2K | $5.35 | $12K | 160K |
| 2026-08-03 | GUGGENHIME ANDREW | PRESIDENT AND CFO | Sell | 3K | $54.18 | $165K | 105K |
| 2026-08-03 | GUGGENHIME ANDREW | PRESIDENT AND CFO | Sell | 7K | $53.76 | $374K | 108K |
| 2026-08-03 | GUGGENHIME ANDREW | PRESIDENT AND CFO | Option exercise | 10K | $5.35 | $54K | 115K |
| 2026-06-15 | BRANDICOURT OLIVIER | n/a | Grant | 2K | $0.00 | $0 | 5K |
| 2026-06-01 | Wassil Jim | CHIEF OPERATING OFFICER | Sell | 301 | $50.26 | $15K | 158K |
| 2026-06-01 | Wassil Jim | CHIEF OPERATING OFFICER | Sell | 2K | $49.40 | $96K | 159K |
| 2026-05-01 | Wassil Jim | CHIEF OPERATING OFFICER | Sell | 2K | $56.83 | $128K | 161K |
| 2026-04-07 | Cowan Elvia | SVP, Finance & CAO | Sell | 3K | $60.00 | $180K | 29K |
| 2026-04-07 | Cowan Elvia | SVP, Finance & CAO | Option exercise | 3K | $25.92 | $78K | 32K |
| 2026-04-01 | Wassil Jim | CHIEF OPERATING OFFICER | Sell | 838 | $58.93 | $49K | 163K |
| 2026-04-01 | Wassil Jim | CHIEF OPERATING OFFICER | Sell | 1K | $58.14 | $82K | 165K |
| 2026-03-17 | Cowan Elvia | SVP, Finance & CAO | Sell | 405 | $56.26 | $23K | 29K |
| 2026-03-17 | Cowan Elvia | SVP, Finance & CAO | Sell | 1K | $55.39 | $82K | 29K |
| 2026-03-11 | Cowan Elvia | SVP, Finance & CAO | Sell | 3K | $58.59 | $146K | 31K |
| 2026-03-11 | Cowan Elvia | SVP, Finance & CAO | Option exercise | 3K | $25.92 | $65K | 33K |
| 2026-03-10 | Wassil Jim | CHIEF OPERATING OFFICER | Sell | 5K | $59.16 | $294K | 167K |
| 2026-03-10 | Wassil Jim | CHIEF OPERATING OFFICER | Sell | 2K | $58.32 | $142K | 172K |
| 2026-03-09 | Wassil Jim | CHIEF OPERATING OFFICER | Tax withholding | 975 | $59.32 | $58K | 174K |
| 2026-03-09 | PICKERING GRANT | CHIEF EXECUTIVE OFFICER | Tax withholding | 4K | $59.32 | $219K | 497K |
| 2026-03-09 | GUGGENHIME ANDREW | PRESIDENT AND CFO | Tax withholding | 1K | $59.32 | $61K | 104K |
| 2026-03-09 | Dhaliwal Harpreet S. | Chief Technical Ops Officer | Tax withholding | 604 | $59.32 | $36K | 76K |
| 2026-03-09 | Cowan Elvia | SVP, Finance & CAO | Tax withholding | 495 | $59.32 | $29K | 31K |
| 2026-03-02 | Wassil Jim | CHIEF OPERATING OFFICER | Tax withholding | 1K | $61.98 | $63K | 175K |
| 2026-03-02 | PICKERING GRANT | CHIEF EXECUTIVE OFFICER | Tax withholding | 3K | $61.98 | $157K | 501K |
| 2026-03-02 | GUGGENHIME ANDREW | PRESIDENT AND CFO | Tax withholding | 1K | $61.98 | $63K | 105K |
| 2026-03-02 | Dhaliwal Harpreet S. | Chief Technical Ops Officer | Tax withholding | 465 | $61.98 | $29K | 77K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are the rarer, stronger signal.
Planned sales (Form 144)
Newest first. JSON7 Form 144 notices on file for PCVX worth $3.0M at the prices reported; 7 in the last 90 days worth $3.0M. Latest: Wassil Jim filed on 2026-09-09 to sell 1,334 shares ($80K) from 2026-09-09.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-09-09 | Wassil JimOfficer | 1K | $80K | 0.001% | 2026-09-09 | UBS Financial Services, Inc. |
| 2026-09-04 | Wassil JimOfficer | 1K | $82K | 0.001% | 2026-09-04 | UBS Financial Services, Inc. |
| 2026-09-01 | Wassil JimOfficer | 3K | $210K | 0.002% | 2026-09-01 | UBS Financial Services, Inc. |
| 2026-08-05 | Dhaliwal Harpreet S.Officer | 17K | $935K | 0.012% | 2026-08-05 | UBS Financial Services, Inc. |
| 2026-08-03 | Wassil JimOfficer | 2K | $121K | 0.002% | 2026-08-03 | UBS Financial Services, Inc. |
| 2026-08-03 | GUGGENHIME ANDREWOfficer | 10K | $540K | 0.007% | 2026-08-03 | UBS Financial Services, Inc |
| 2026-07-27 | PICKERING GRANTOfficer, Director | 18K | $997K | 0.013% | 2026-07-27 | UBS Financial Services, Inc. |
Large holders (13D and 13G)
One row per reporting person, newest filing first. JSON3 holders above 5% have filed on PCVX, all on Schedule 13G (passive). The largest reported stake is FMR LLC at 14.4% of the class (20,798,907 shares), filed 2026-08-06 for an event on 2026-06-30.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-08-11 | 13G/Ano. 11 | JANUS HENDERSON GROUP Ltd.parent holding company | 18.0M | 12.1% | 2026-07-31 |
| 2026-08-07 | 13G/Ano. 10 | JANUS HENDERSON GROUP Ltd.parent holding company | 66K | 0.1% | 2026-07-31 |
| 2026-08-06 | 13G/Ano. 10 | FMR LLCparent holding company | 20.8M | 14.4% | 2026-06-30 |
| 2026-08-06 | 13G/Ano. 10 | Abigail P. Johnsonindividual | 20.8M | 14.4% | 2026-06-30 |
13F holders
Tracked managers holding PCVX at their latest 13F. JSON7 of the 30 tracked managers held PCVX at their latest 13F, $161.3M in total at quarter-end prices. D. E. Shaw & Co. is the largest at $110.6M (0.1% of its portfolio) as of 2026-06-30. Over the prior quarter 4 added shares and 3 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| D. E. Shaw & Co. | 2026-06-30 | 1.9M | $110.6M | 0.05% | -963K |
| Citadel Advisors | 2026-06-30 | 358K | $20.8M | 0.00% | +161K |
| Two Sigma Investments | 2026-06-30 | 274K | $15.9M | 0.01% | +163K |
| Millennium Management | 2026-06-30 | 137K | $7.9M | 0.00% | -157K |
| Bridgewater Associates | 2026-06-30 | 50K | $2.9M | 0.01% | +37K |
| AQR Capital Management | 2026-06-30 | 35K | $2.0M | 0.00% | +9K |
| Renaissance Technologies | 2026-06-30 | 20K | $1.1M | 0.00% | -35K |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
Financials
SEC XBRL, as filed. JSONIn FY 2025 it generated -$655.6M of operating cash flow.
- Cash
- $183.2M
- Equity
- $2.76B
- Total assets
- $3.14B
- Shares outstanding
- 148,805,278
Quarterly, last 8 quarters
| Quarter | Period end | Revenue | Net income | Margin | Diluted EPS |
|---|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | n/a | -$284.3M | n/a | -1.97 |
| Q1 2026 | 2026-03-31 | n/a | -$320.6M | n/a | -2.30 |
| Q3 2025 | 2025-09-30 | n/a | -$212.8M | n/a | -1.56 |
| Q2 2025 | 2025-06-30 | n/a | -$166.6M | n/a | -1.22 |
| Q1 2025 | 2025-03-31 | n/a | -$140.7M | n/a | -1.04 |
| Q3 2024 | 2024-09-30 | n/a | -$103.1M | n/a | -0.83 |
| Q2 2024 | 2024-06-30 | n/a | -$128.7M | n/a | -1.10 |
| Q1 2024 | 2024-03-31 | n/a | -$95.0M | n/a | -0.85 |
Fiscal years, with buybacks and dividends
| Fiscal year | Ends | Revenue | Net income | Operating cash flow | Capex | Buybacks | Dividends |
|---|---|---|---|---|---|---|---|
| FY 2025 | 2025-12-31 | n/a | n/a | -$655.6M | $13.7M | n/a | n/a |
| FY 2024 | 2024-12-31 | n/a | n/a | -$452.6M | $22.4M | n/a | n/a |
| FY 2023 | 2023-12-31 | n/a | n/a | -$296.8M | $16.1M | n/a | n/a |
| FY 2022 | 2022-12-31 | n/a | n/a | -$170.6M | $5.8M | n/a | n/a |
| FY 2021 | 2021-12-31 | n/a | n/a | -$121.4M | $6.6M | n/a | n/a |
Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are cash paid to repurchase common stock in the year (XBRL PaymentsForRepurchaseOfCommonStock), not authorizations. Balance sheet lines are as of 2026-06-30; shares outstanding as of 2026-08-03 from the cover page.
What this page is
Vaxcyte, Inc. in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page pulls every series the site collects for one ticker onto one URL, keyed by the SEC's own ticker list, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a summary sentence built from the rows (last value, change, range with dates) and its own JSON and CSV links. Nothing on the page is written by a model; the sentences change only when the data does. A page exists only for companies with data in at least two series, and every section says when its source last updated.
This page follows Vaxcyte, Inc. (PCVX), SEC CIK 1649094, listed on Nasdaq, classified by the SEC as biological products, (no diagnostic substances). The cross-market tables live on the short interest and insider transactions hubs.
Source and method
- Short interest
- FINRA consolidated short interestTwice a month, about eight business days after settlement. Latest 2026-08-14.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesEvery trading day, loaded the following morning. Latest 2026-09-11.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataTwice a month, a few weeks after the half month ends. Latest 2026-08-06.JSON and CSV
- Planned sales
- SEC EDGAR Form 144EDGAR read every 30 minutes; a notice is filed on or before the sell order. Latest 2026-09-09.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GEDGAR read every 30 minutes; 13D within five business days of crossing 5%, 13G on the passive schedule. Latest 2026-08-11.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRQuarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Financials
- SEC XBRL company factsRefreshed weekly from the SEC's structured data; values are as filed in the 10-Q and 10-K. Latest 2026-06-30.JSON and CSV
- Insider trades
- SEC EDGAR Form 4EDGAR read every 30 minutes; filings are due two business days after the trade. Latest 2026-09-08.JSON and CSV
- Company record
- EDGAR filing index for CIK 1649094Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 30 requests a minute without a key, 120 a minute with a key from a free account.
Data checks. Every dataset is checked against its source once a day. This dataset passed the last run, 13 Sep 05:40 UTC.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a crowded short are the combination that has historically preceded squeezes; insider sells next to a crowded short are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as biological products, (no diagnostic substances)
- KYMRKymera Therapeutics, Inc.
- ADPTAdaptive Biotechnologies Corp
- TWSTTwist Bioscience Corp
- HALOHALOZYME THERAPEUTICS, INC.
- KRYSKrystal Biotech, Inc.
- NBIXNEUROCRINE BIOSCIENCES INC
- RVMDRevolution Medicines, Inc.
- AMGNAMGEN INC
- MAZEMaze Therapeutics, Inc.
- GILDGILEAD SCIENCES, INC.
- RXRXRECURSION PHARMACEUTICALS, INC.
- APGEApogee Therapeutics, Inc.
- FENCFENNEC PHARMACEUTICALS INC.
- BIIBBIOGEN INC.
- VORVor Biopharma Inc.
- EXELEXELIXIS, INC.
- SRRKScholar Rock Holding Corp
- ADMAADMA BIOLOGICS, INC.
- VCELVericel Corp
- TECHBIO-TECHNE Corp
- ARTVArtiva Biotherapeutics, Inc.
- BCRXBIOCRYST PHARMACEUTICALS INC
- VIRVir Biotechnology, Inc.
- IOVAIOVANCE BIOTHERAPEUTICS, INC.
Datasets
Frequently Asked Questions
How much of PCVX is sold short?
What is PCVX's daily short volume?
Does PCVX have fails to deliver?
Are PCVX insiders buying or selling?
Have PCVX insiders filed to sell?
Who owns more than 5% of PCVX?
What did PCVX report last quarter?
Which funds hold PCVX?
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.